BCL2L11 and non-small cell lung carcinoma: Overall 11.3% and 17.0% EGFR‐mutant patients with advanced‐stage NSCLC in the CTONG0901 and GLCI cohorts had BIM deletion polymorphism, respectively, which had no relationship with any clinical or pathological factors.